Allergy and Immunology · Westfield, MA
NPI
1528094372
Since 2006
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
212 Southampton Rd Unit B
Westfield, MA, 01085
Phone (413) 628-5187
Groups this clinician bills Medicare through
Medicare paid, 2024
$63K
6,024 services
Medicare patients, 2024
411
Average age 70
Drug cost, 2024
$2.6M
2,237 prescriptions
Company payments, 2025
$7,567
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vanessa L Vanstee was code 95004 (test - miscellaneous), 2,459 times for 53 patients. In total Vanessa L Vanstee billed 6,024 services in 27 codes, and Medicare paid $63K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 2,459 | 53 | $2.40 | $5,901 |
| 95117 Treatment - Miscellaneous | Office | 1,722 | 218 | $8.94 | $15K |
| 95024 Test - Miscellaneous | Office | 386 | 44 | $6.10 | $2,354 |
| 95115 Treatment - Miscellaneous | Office | 338 | 85 | $7.70 | $2,602 |
| 99213 Office E&M - Established | Office | 213 | 166 | $63.09 | $13K |
| 99214 Office E&M - Established | Office | 146 | 100 | $95.53 | $14K |
| 96372 Injection Administration | Office | 140 | 23 | $10.54 | $1,475 |
| 94010 Pulmonary Function Testing | Office | 48 | 24 | $9.64 | $463 |
| 99203 Office E&M - New | Office | 38 | 38 | $75.58 | $2,872 |
By year: 2022 $66K for 5,711 services; 2023 $68K for 5,650 services; 2024 $63K for 6,024 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vanessa L Vanstee prescribed most often to Medicare patients was Montelukast Sodium, with 206 prescriptions and refills. In total Vanessa L Vanstee wrote 2,237 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 206 | 494 | 57 | $3,093 |
| Azelastine Hcl Generic | 157 | 322 | 63 | $4,516 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 155 | 165 | 81 | $4,229 |
| Xolair Omalizumab | 153 | 161 | 15 | $446K |
| Fluticasone Propionate Generic | 139 | 258 | 55 | $2,512 |
| Epinephrine Generic | 118 | 119 | 79 | $26K |
| Advair Hfa Fluticasone Propion/Salmeterol | 93 | 106 | 20 | $35K |
| Breo Ellipta Fluticasone/Vilanterol | 92 | 134 | 19 | $53K |
| Levocetirizine Dihydrochloride Generic | 81 | 182 | 25 | $2,433 |
| Prednisone Generic | 79 | 81 | 39 | $503 |
| Ipratropium Bromide Generic | 59 | 107 | 33 | $2,008 |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | 52 | 52 | Under 11 | $217K |
| Famotidine Generic | 51 | 109 | 16 | $1,162 |
| Cromolyn Sodium Generic | 50 | 72 | 16 | $10K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 46 | 64 | Under 11 | $8,474 |
Brand drugs: 1,018 claims; generic drugs: 1,219 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vanessa L Vanstee $7,567 ($7,567 in general payments such as food, travel and fees) from 16 companies. The largest payer was Novartis Pharmaceuticals Corporation with $5,904.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 18 | $5,904 |
| AstraZeneca Pharmaceuticals LP AZN | 18 | $426 |
| Regeneron Healthcare Solutions, Inc. REGN | 12 | $371 |
| GC Biopharma USA, Inc. 006280.KS | 6 | $134 |
| Lilly USA, LLC LLY | 4 | $116 |
| Amgen Inc. AMGN | 5 | $109 |
| Pharming Healthcare, Inc. | 4 | $99.78 |
| CSL Behring CSL.AX | 3 | $78.54 |
| GlaxoSmithKline, LLC. GSK | 3 | $64.65 |
| Organon LLC OGN | 2 | $52.94 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.